Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.35 |
| ▸ | CHRNG | P07510 | 1/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | CHRND | Q07001 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11875611 | 0.89 | TEAD4 (0.40) | ACHETDP1SLC6A4KCNH2 | |
| SCHEMBL3987895 | 0.82 | TAAR1 (0.35) | — | |
| SCHEMBL11736293 | 0.77 | SMN1; SMN2 (0.40) | L3MBTL1TDP1 | |
| SCHEMBL11740144 | 0.76 | NOS3 (0.36) | — | |
| SCHEMBL11863652 | 0.74 | LTA4H (0.41) | MAOBMAOATSHRL3MBTL1 | |
| SCHEMBL11860662 | 0.74 | MAOA (0.40) | MAOBMAOASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL15908233 | 0.73 | MAOB (0.40) | MAOBMAOASLC6A2SLC6A3CHRNA1 | |
| SCHEMBL2082178 | 0.71 | LMNA (0.42) | MAOBMAOASLC6A2SLC6A3CHRNA1 | |
| SCHEMBL11877787 | 0.70 | NPC1 (0.37) | — | |
| SCHEMBL14081492 | 0.67 | OPRM1 (0.42) | TSHRL3MBTL1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014732-A1 | Combination of an aldosterone receptor antagonist and an anti-diabetic agent | PHARMACIA CORPORATION (US) | 2005-01-20 | — | — | US | disclosed |
| EP-0641319-A1 | N- N'-(5-AMINO-4-HYDROXY-ACYLOYL)-$g(a)-AMINOACYLOYL] SUBSTITUTED HETEROCYCLES AND THEIR USE AS ANTIVIRAL AGENTS | Pfizer Limited (GB) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993023373-A1 | N-[N'-(5-AMINO-4-HYDROXY-ACYLOYL)-α-AMINOACYLOYL] SUBSTITUTED HETEROCYCLES AND THEIR USE AS ANTIVIRAL AGENTS | PFIZER LIMITED (GB) | 1993-11-25 | — | — | WO | disclosed |
| EP-0104572-A1 | Benzyl ethers of phenol Mannich bases, process for their production, their use and pharmaceutical preparations based on these compounds, intermediates and process for their production | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014732-A1 | Combination of an aldosterone receptor antagonist and an anti-diabetic agent | NR3C2, REN, AGTR1 | MAOB 4027/4885MAOA 4138/4885SLC6A2 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.